Last reviewed · How we verify
PlexoZome® Levagen® topical spray solution
PlexoZome® Levagen® topical spray solution is a Small molecule drug developed by RDC Clinical Pty Ltd. It is currently FDA-approved.
At a glance
| Generic name | PlexoZome® Levagen® topical spray solution |
|---|---|
| Sponsor | RDC Clinical Pty Ltd |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PlexoZome® Levagen® topical spray solution CI brief — competitive landscape report
- PlexoZome® Levagen® topical spray solution updates RSS · CI watch RSS
- RDC Clinical Pty Ltd portfolio CI
Frequently asked questions about PlexoZome® Levagen® topical spray solution
What is PlexoZome® Levagen® topical spray solution?
PlexoZome® Levagen® topical spray solution is a Small molecule drug developed by RDC Clinical Pty Ltd.
Who makes PlexoZome® Levagen® topical spray solution?
PlexoZome® Levagen® topical spray solution is developed and marketed by RDC Clinical Pty Ltd (see full RDC Clinical Pty Ltd pipeline at /company/rdc-clinical-pty-ltd).
What development phase is PlexoZome® Levagen® topical spray solution in?
PlexoZome® Levagen® topical spray solution is FDA-approved (marketed).
Related
- Manufacturer: RDC Clinical Pty Ltd — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing